bortezomib
Bortezomib is a proteasome inhibitor used to treat Multiple Myeloma, Mantle-Cell Lymphoma.
Proteasome Inhibitor · by Accord Hlthcare
Generic of Velcade
Key facts
- Active ingredient
- Bortezomib
- Drug class
- Proteasome Inhibitor
- Form
- Injectable, Powder
- Strength
- Bortezomib 3.5MG/VIAL
- Type
- Prescription (Rx)
- Brand or generic
- Generic
- May treat
- multiple myeloma, mantle-cell lymphoma
- Manufacturer
- Accord Hlthcare
- FDA application
- ANDA204405
- Availability
- Discontinued (per FDA)
Drug class
May treat (source: NIH RxClass)
See how Bortezomib ranks — best-rated proteasome inhibitor for:
Dosage forms
Injectable and Powder
The forms currently marketed in the U.S., per the FDA National Drug Code Directory.
Ways to save
Ask for the generic
Same active ingredient, far cheaper. Is there a generic? →
Request a 90-day supply
Bulk fills usually lower the per-dose price vs monthly refills.
Use copay cards
Manufacturer copay cards & patient-assistance programs — especially for brand drugs.
Compare alternatives
A same-class option may cost less. See alternatives →
Frequently asked questions
- What does Bortezomib treat?
- Bortezomib (Bortezomib) may be used to treat multiple myeloma, mantle-cell lymphoma, based on NIH RxClass drug-classification data (conditions a drug may treat — not a verbatim copy of the FDA-approved label). This is general reference, not medical advice.
- Is there a coupon or discount for Bortezomib?
- pharmaranks is an independent ratings site, not a pharmacy — we don't issue coupons or sell Bortezomib. To pay less, Bortezomib is already a generic — usually the lowest-cost version — so the main levers are comparing cash prices between pharmacies and using a pharmacy discount-card service. Prices vary by pharmacy, insurance, and location, so always confirm at the counter. This is general reference, not medical or financial advice.
- Who makes Bortezomib?
- Bortezomib is marketed by Accord Hlthcare. You can see Accord Hlthcare's full profile, rating, and other products on pharmaranks.
- Is Bortezomib a brand-name or generic drug?
- Bortezomib is a generic medication; its active ingredient is Bortezomib. Generics contain the same active ingredient as the brand-name original and are usually lower cost.
- Is Bortezomib available over the counter?
- No. Bortezomib is a prescription (Rx) medication in the US — you need a prescription from a licensed clinician (in person or via telehealth); it isn't sold over the counter. For some conditions there are OTC alternatives — ask your pharmacist.
- What forms does Bortezomib come in?
- Bortezomib is currently marketed as injectable and powder, per the FDA's National Drug Code Directory.
- What class of drug is Bortezomib?
- Bortezomib is classified as proteasome inhibitor, per the FDA's Established Pharmacologic Class.
- Is Bortezomib FDA-registered?
- Bortezomib is on record with the U.S. FDA under application number ANDA204405. You can verify this on its official FDA label.
Information is sourced from public FDA regulatory data. Provided for general reference only — not medical advice. Always consult a licensed professional and the current prescribing information.
What people report to the FDA about Bortezomib
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 34,522 reports naming Bortezomib, and the FDA flagged 95% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- plasma cell myeloma5,282 reports
- neuropathy peripheral1,962 reports
- thrombocytopenia1,838 reports
- pneumonia1,654 reports
- diarrhoea1,469 reports
- neutropenia1,466 reports
- fatigue1,237 reports
- anaemia1,182 reports
Read these as a signal, not a rate. A report does not mean Bortezomib caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label.
Source: openFDA drug/event (FAERS), retrieved September 25, 2026.
Reviews
No reviews yet. Be the first to write one.
People also viewed
Compare Bortezomib head-to-head
Browse medications A–Z
Research products from A to Z, compare independent ratings, and find alternatives.
bortezomib
New